FDA: Zephyr Endobronchial Valve approved for severe emphysema

FDA: zephyr endobronchial valve approved for severe emphysema
(HealthDay)—A new device, the Zephyr Endobronchial Valve (Zephyr Valve), has been approved by the U.S. Food and Drug Administration for the treatment of breathing difficulties associated with severe emphysema.

During a procedure in a hospital setting, the Zephyr Valves are placed into the diseased areas of the lung airways using a flexible bronchoscope. The is designed to prevent air from entering the damaged parts of the lung and allow the escape of trapped air and fluids.

Data were reviewed from a multicenter study of 190 patients with . A total of 128 patients were treated with Zephyr Valves and medical management, including medications and pulmonary rehabilitation, while the (62 patients) received alone. At one year, 47.7 percent of patients treated with the Zephyr Valves and 16.8 percent of the control group experienced at least a 15 percent improvement in their pulmonary function scores. Approval for the device was granted to Pulmonx.

"Treatment options are limited for people with emphysema who have severe symptoms that have not improved from taking medicines," Tina Kiang, Ph.D., acting director of the Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices in the FDA's Center for Devices and Radiological Health, said in a statement. "This novel device is a less invasive treatment that expands the options available to patients."


Explore further

Trial demonstrates effectiveness of minimally invasive emphysema treatment

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA: Zephyr Endobronchial Valve approved for severe emphysema (2018, July 8) retrieved 19 May 2019 from https://medicalxpress.com/news/2018-07-fda-zephyr-endobronchial-valve-severe.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more